MétaCan
Menu
Back to cohort

S3200 ABP 710, a Biosimilar to Infliximab Reference Product: Supporting Extrapolation of Indications With a Focus on Crohn’s Disease

2020· article· en· W3093529184 on OpenAlexaff
Walter Reinisch, Smita Halder, Waliul I. Khan, Xuanyu Wang, Scott Kuhns

Bibliographic record

VenueThe American Journal of Gastroenterology · 2020
Typearticle
Languageen
FieldImmunology and Microbiology
TopicBiosimilars and Bioanalytical Methods
Canadian institutionsMcMaster University
Fundersnot available
KeywordsMedicineAntibody-dependent cell-mediated cytotoxicityInfliximabImmunologyPeripheral blood mononuclear cellTumor necrosis factor alphaImmune systemPharmacologyAntibodyMonoclonal antibodyBiologyIn vitroBiochemistry

Abstract

fetched live from OpenAlex

INTRODUCTION: ABP 710 (US: AVSOLA™ [infliximab-axxq]) is an approved biosimilar to infliximab reference product (RP). The primary mechanism of action (MOA) of infliximab RP is mediated by binding to soluble tumor necrosis factor (TNF) alpha, inhibiting its proinflammatory signaling. Secondary mechanisms mediated by binding to membrane bound (mb) TNF alpha may play a role in inflammatory disease as demonstrated by reverse signaling, mixed lymphocyte reactions (MLRs) and effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity. Here we examined specific ex-vivo functional studies to support extrapolation of ABP 710 to Crohn’s disease (CD). METHODS: Fecal calprotectin (FCal) levels were measured by ELISA and phenotyping of peripheral blood mononuclear cells (PBMCs) was carried out in healthy volunteers and in patients with CD by flow cytometry. ADCC was assessed in PBMCs isolated from 5 healthy volunteers and 3 patients with CD. Multiple lots of ABP 710 and RP sourced from the United States (US) and the European Union (EU) were compared for ADCC. RESULTS: FCal levels were higher in patients with CD as compared to control and were also higher in patients with CD with higher baseline levels of C-reactive protein (CRP). Peripheral blood immunophenotyping of patients with CD also demonstrated that most immune cell (granulocytes, lymphocytes, natural killer cells and monocytes) markers were similarly higher in patients with CD and with high CRP as compared to control (see Table). As with FCal, higher baseline CRP was associated with an increase in blood immune markers. ADCC data from PBMCs isolated from 5 healthy volunteers and 3 CD patients demonstrated similar function in ABP 710 as compared with the RP (US and EU) in all samples from healthy volunteers and in 2 out of 3 samples from patients with CD. CONCLUSION: ABP 710 infliximab RP biosimilar has previously been shown to be highly similar to the RP in efficacy, safety and immunogenicity. We have demonstrated that similarity extends to biological activity across key MOAs, including those mediated through mbTNF alpha which may be important for the efficacy of infliximab in patients with CD. Coupled with previously reported analytical similarity assessments, similar ex vivo ADCC activity in PBMCs isolated from healthy volunteers and patients with CD despite differences in physiological and blood phenotype indicators, contribute to the totality of evidence supporting efficacy of ABP 710 in CD.Table 1

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.583
Threshold uncertainty score0.374

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.024
GPT teacher head0.288
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicBiosimilars and Bioanalytical MethodsFrench-language works237,207